obstructive sleep apnea, FDA

In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Sleep apnea can significantly increase health risks ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment.
The FDA's approval of tirzepatide for the treatment of obstructive sleep apnea is based on a randomized, double-blind, placebo-controlled study in 469 adults without type 2 diabetes, in which ...